Abstract
Quantity and distribution of transgene-expressing tumor cells are central issues in cancer gene therapy. These are critical for the efficiency of tumor killing and for the bystander effect. In an attempt to combine the advantages of a potent bioactivating “suicide” gene with a marker gene for living cells, cDNA encoding cytochrome CYP4B1 was fused to the green fluorescent protein (GFP) cDNA. The resulting chimeric fusion protein, 4B1EGFP, was expressed in rodent and human glioma cell lines in culture. The ability of this recombinant enzyme to destroy tumor cells by converting the prodrug 4-ipomeanol (4-IM) into alkylating metabolites was evaluated in comparison with the cytotoxicity of the native CYP4B1 enzyme. The most sensitive 4B1EGFP-expressing glioma cell clone had a LD50 of 0.75 µg/ml for 4-IM, as compared to a 4-IM LD50 of 0.5 ag/ml in glioma cells expressing the native CYP4B1. A strong bystander effect mediated by cell-to-cell contact was present in the 4B1EGFP clones, allowing for more than 50% bystander kill at a ratio of expressing to non-expressing cells of 1:100. A herpes-simplex amplicon (pHSVPrPUCAHind) was constructed with the 4B1EGFP fusion protein, and recombinant helper-free HSV particles were packaged in Vero cells. Fisher 344 rats were inoculated with 4 × 105 9L tumor cells to produce epidural tumor. Recombinant HSV particles were injected into the tumor at a dose of 1 × 107 pfu. Tumor was resected in living anesthetized animals 24, 48, and 72 hours after virus injection, and cryostat sections were evaluated by fluorescent microscopy. HSV-mediated delivery of the fusion protein to tumor cells was successfully demonstrated. In conclusion, the chimeric fusion protein 4B1EGFP retains essentially all features of the native CYP4B1 enzyme, and, moreover, offers advantages in term of gene transfer visualization, which may lead to improvement of gene transfer strategies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan P A, Paulus W, Chiocca EA, Breakefield XO,1995: Gene therapy for brain tumors. Brain Pathol 5, 345–381
Tamiya T, Ono Y, Wei MX, Mroz PJ, Moolten FL, Chiocca EA, 1996: Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther 3, 155–162
Huber BE, Austin EA, Richards CA, Davis ST, Good SS, 1994: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91, 8302–8306
Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA, 1994: Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5, 969–978
Moolten FL, 1986: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46, 5276–5281
Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE, 1995: Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55, 4808–4812
Boyd MR, Wilson BJ, Harris TM, 1972: Confirmation by chemical synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. Nature New Biol 236, 158–159
Boyd MR, 1976: Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: mechanism of action of the lung-toxic furan, 4-ipomeanol. Environ. Health Perspect. 16, 127–138
Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC, 1994: Green fluorescent protein as a marker for gene expression. Science 263, 802–805
Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller AI, 1996: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 70, 7190–7197
Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Chiocca EA, Philpot RM, Breakefield XO, 1997: Prodrug activation therapy of malignant glioma with cytochrome P450 4B1. Human Gene Ther — in press
Dutcher JS, Boyd MR, 1979: Species and strain differences in target organ alkylation and toxicities by 4-Ipomeanol: predictive value of covalent binding in studies of target organ toxicities by reactive metabolites. Biochem Pharmacol 28, 3367–3372
Statham CN, Boyd MR, 1982: Distribution and metabolism of the pulmonary alkylating agent and cytotoxic 4-ipomeanol, in control and diethylmaleate-treated rats. Biochem Pharmacol 31, 1585–1589
Verschoyle RD, Philpot RM, Wolf CR, Dinsdale D, 1993: CYP4B1 activates 4-Ipomeanol in rat lung. Toxicol Appl Pharmacol 123, 193–198
Czerwinski M, McLemore TL, Philpot RM, Nhamburo PT, Korzekwa K, Gelboin HV, Gonzalez FJ, 1991: Metabolic activation of 4-Ipomeanol by complementary DNA-expressed human cytochromes p-450: evidence for species-specific metabolism. Cancer Res 51, 4636–4638
Boyd MR, Burka LT, 1978: In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. J Pharmacol Exp Ther 207, 687–697
Smith PB, Tiano HF, Nesnow S, Boyd MR, Philpot RM, Langenbach R, 1995: 4-Ipomeanol and 2-ami-noanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1. Biochem Pharmacol 50, 1567–1575
Vanderslice RR, Domin BA, Carver GT, Philpot RM, 1987: Species-dependent expression and induction of homologues of rabbit cytochrome p-450 isozyme 5 in liver and lung. Mol Pharmacol 31, 320–325
Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN, 1993: The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53, 5274–5283
Manome Y, Wen PY, Chen L, Tanaka T, Dong Y, Yamazoe M, Hirshowitz A, Kufe DW, Fine HA, 1996: Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther 3, 513–520
Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD, Dewhirst MW, 1995: A pial window model for the intracranial study of human glioma microvascular function. Neurosurgery 36, 976–984
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rainov, N.G., Sena-Esteves, M., Fraefel, C., Dobberstein, KU., Chiocca, E.A., Breakefield, X.O. (1998). A Chimeric Fusion Protein of Cytochrome CYP4B1 and Green Fluorescent Protein for Detection of Pro-Drug Activating Gene Delivery and for Gene Therapy in Malignant Glioma. In: Walden, P., Trefzer, U., Sterry, W., Farzaneh, F., Zambon, P. (eds) Gene Therapy of Cancer. Advances in Experimental Medicine and Biology, vol 451. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5357-1_61
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5357-1_61
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7444-2
Online ISBN: 978-1-4615-5357-1
eBook Packages: Springer Book Archive